These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38387938)

  • 21. [Research Progress of Chimeric Antigen Receptor Modified NK Cells in the Treatment of Acute Myeloid Leukemia --Review].
    Peng XR; Cheng J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1905-1909. PubMed ID: 38071081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NK cells and exercise: implications for cancer immunotherapy and survivorship.
    Bigley AB; Simpson RJ
    Discov Med; 2015 Jun; 19(107):433-45. PubMed ID: 26175401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.
    Carbone E; Neri P; Mesuraca M; Fulciniti MT; Otsuki T; Pende D; Groh V; Spies T; Pollio G; Cosman D; Catalano L; Tassone P; Rotoli B; Venuta S
    Blood; 2005 Jan; 105(1):251-8. PubMed ID: 15328155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma.
    Van Oekelen O; Amatangelo M; Guo M; Upadhyaya B; Cribbs AP; Kelly G; Patel M; Kim-Schulze S; Flynt E; Lagana A; Gooding S; Merad M; Jagganath S; Pierceall WE; Oppermann U; Thakurta A; Parekh S
    Cell Rep Med; 2024 Jun; 5(6):101584. PubMed ID: 38776911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.
    Müller LME; Migneco G; Scott GB; Down J; King S; Askar B; Jennings V; Oyajobi B; Scott K; West E; Ralph C; Samson A; Ilett EJ; Muthana M; Coffey M; Melcher A; Parrish C; Cook G; Lawson M; Errington-Mais F
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Natural Killer Cells for Tumor Immunotherapy.
    Zhang C; Hu Y; Shi C
    Front Immunol; 2020; 11():60. PubMed ID: 32140153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022.
    Huang R; Wen Q; Zhang X
    J Hematol Oncol; 2023 Apr; 16(1):35. PubMed ID: 37029381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple Myeloma and the Immune Microenvironment.
    Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
    Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma.
    Reina-Ortiz C; Giraldos D; Azaceta G; Palomera L; Marzo I; Naval J; Villalba M; Anel A
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Application of Chimeric Antigen Receptor-Modified CAR-T/NK Cells to Treatment of Multiple Myeloma].
    Wang L; Ou jF; Bai H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):568-72. PubMed ID: 25948226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Driving natural killer cell-based cancer immunotherapy for cancer treatment: An arduous journey to promising ground.
    Jiang D; Zhang J; Mao Z; Shi J; Ma P
    Biomed Pharmacother; 2023 Sep; 165():115004. PubMed ID: 37352703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Research advance on adaptive immune therapy with natural killer cells--review].
    Chen GH; Wu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):798-802. PubMed ID: 20561454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells.
    Edri A; Ben-Haim N; Hailu A; Brycman N; Berhani-Zipori O; Rifman J; Cohen S; Yackoubov D; Rosenberg M; Simantov R; Teru H; Kurata K; Anderson KC; Hendel A; Pato A; Geffen Y
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
    El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
    Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A.
    Sarkar S; van Gelder M; Noort W; Xu Y; Rouschop KM; Groen R; Schouten HC; Tilanus MG; Germeraad WT; Martens AC; Bos GM; Wieten L
    Cancer Immunol Immunother; 2015 Aug; 64(8):951-63. PubMed ID: 25920521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extracellular vesicles derived from immortalized human natural killer cell line NK3.3 as a novel therapeutic for multiple myeloma.
    Matchett EC; Kornbluth J
    Front Immunol; 2023; 14():1265101. PubMed ID: 37818374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential of NK cells in multiple Myeloma therapy.
    Khan AM; Devarakonda S; Bumma N; Chaudhry M; Benson DM
    Expert Rev Hematol; 2019 Jun; 12(6):425-435. PubMed ID: 31070067
    [No Abstract]   [Full Text] [Related]  

  • 39. Cancer immunotherapy via stem cell-derived NK cells.
    Hosseini F; Ahmadvand M; Karimi R; Mousavi SA; Ai J; Nikbakht M
    Immunotherapy; 2023 Aug; 15(12):963-973. PubMed ID: 37337708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor.
    Sutlu T; Stellan B; Gilljam M; Quezada HC; Nahi H; Gahrton G; Alici E
    Cytotherapy; 2010 Dec; 12(8):1044-55. PubMed ID: 20795758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.